Pharmacokinetics of tiqueside (beta-tigogenin cellobioside) in dogs, rats, rabbits, and monkeys.

Tiqueside (CP-88,818, beta-tigogenin cellobioside) is an effective cholesterol absorption inhibitor that may be useful in the treatment of hypercholesteremia. We have investigated the pharmacokinetics of tiqueside in dogs, rats, rabbits, and monkeys. In dogs, the volume of distribution (Vdss) was 2.11 L/kg, clearance was 0.58 mL/min-kg, and half-life was 45 h following a 1.4 mg/kg intravenous dose. Absolute bioavailability in fed dogs decreased from 6.7% for a 30 mg/kg dose to 1.7% for a 375 mg/kg dose. The oral bioavailability at a dose of 375 mg/kg was approximately 4-fold lower in fasted dogs than fed dogs. AUC-(0-24) for doses up to 2000 mg/kg were only slightly greater than AUC-(0-24) for a 375 mg/kg dose. In rats dosed intravenously at 8.0 mg/kg, Vdss was 3.52 L/kg, clearance was 14.6 mL/min-kg, and half-life was 3.6 h. Estimated bioavailability for rats dosed in feed at 250-2000 mg/kg/day was less than 0.5%. In rabbits dosed at 4.0 mg/kg i.v., Vdss was 2.95 L/kg, clearance was 0.59 mL/min-kg, and half-life was 61 h. Bioavailability for rabbits dosed in feed at 62.5 or 125 mg/kg/day was approximately 7%. Systemic exposure in rhesus monkeys after oral dosing was lower than that for dogs and rabbits. Thus, low systemic exposure to tiqueside following oral administration has been demonstrated in several animal species.

Selected ion monitoring analysis of CP-55,940, a cannabinoid derived analgetic agent.

A method is described for the quantification in plasma of CP-55,940, a new non-opiate oral analgetic agent, using capillary gas chromatography/mass spectrometry. After extraction, derivation of the drug and a structural analog internal standard is carried out with trifluoracetyl imidazole. The derivative exhibited excellent gas chromatographic properties. Electron impact yielded an abundant high mass ion whose monitoring permitted the sensitive and specific determination of CP-55,940 down to 0.5 ng ml-1.

Selected ion monitoring assay for meclizine in human plasma.

A method has been developed for the quantification of meclizine in human plasma using gas chromatography mass spectrometry. Pentadeuterated meclizine was synthesized and used as an internal standard. The method gave linear results over a concentration range of 5-200 ng ml-1 and was used to determine plasma levels of meclizine following administration to a male volunteer.